MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Phase 1
Completed
Conditions
Tumors
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02182128

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 207127 NA extended release (10% HPMC)
Drug: BI 207127 NA extended release (20% HPMC)
Drug: BI 207127 NA (TF-I)
Drug: BI 207127 NA (TF-II)
Drug: BI 207127 NA delayed release
Drug: BI 207127 NA extended release (15% PEO)
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
42
Registration Number
NCT02182414

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Phase 1
Completed
Conditions
Genital Neoplasms, Female
Interventions
First Posted Date
2014-07-08
Last Posted Date
2025-01-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
22
Registration Number
NCT02182245

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 207127 NA powder for solution
Drug: Placebo
Drug: BI 207127 NA tablet
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
82
Registration Number
NCT02182388

Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients

Phase 4
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02181946

Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

Phase 3
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2648
Registration Number
NCT02181933

Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo Respimat®
Drug: Berodual® via MDI, high dose
Drug: Berodual® via Respimat®, low dose
Drug: Placebo MDI
Drug: Berodual® via Respimat®, high dose
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
631
Registration Number
NCT02182479

A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting

Phase 3
Completed
Conditions
Myocardial Infarction
Interventions
Drug: Full dose tenecteplase
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1606
Registration Number
NCT02181998

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: 10 mg BI 1356 BS
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
20
Registration Number
NCT02183623

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 201335 NA soft gelatin capsule
Drug: [14C]-BI 201335 NA radiolabelled drug
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02182349
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy